Drugs / VSF1.01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06545175 | Nov 2024 → Oct 2026 expected | hearing loss disorder | Hannover Medical School | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSF1.01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06545175 ↗ |
| Modality | Other / unclassified | “Extracellular Vesicle-enriched Secretome Fraction (VSF1.01)” NCT06545175 ↗ |
| Route | Other | “intracochlear application of VSF1.01” NCT06545175 ↗ |